secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001558370-22-017166
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M
--------------------------------------------------------------------------------

- Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.
- Net loss widened to $6.4M from $2.7M; EBITDA loss $7.1M vs $2.4M loss a year ago.
- Cash and equivalents $232.9M; operating expenses rose to $17.0M from $11.6M on staffing and R&D.
- Reiterated FY2022 guidance: core revenue growth ~30%, SPL program revenue ~$4.0M.
- Cell therapy revenue $7.9M (+27%), drug discovery $2.0M (+4%); SPL revenue fell 62% to $0.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/mxct-20221109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer